FGFR

FGFR Related Products (104):

By Type:	Pan (4) Selective (2)
By Effects:	Inhibitors (94) Modulators (3) Degrader (1)

Cat. No.	Product Name	Effect	Purity

HY-10209

Masitinib	Inhibitor	99.98%
Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.

HY-B0636

Triamcinolone acetonide		99.05%
Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis.

HY-P99010

Bemarituzumab	Inhibitor	≥99.0%
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.

HY-10996A

KHS101 hydrochloride		99.84%
KHS101 hydrochloride could selectively induce a neuronal differentiation phenotype and interacts with transforming acidic coiled-coil-containing protein 3 (TACC3).

HY-P3503A

Vosoritide acetate	Inhibitor	99.72%
Vosoritide (BMN 111) acetate is a natriuretic peptide receptor 2 (NPR2) agonist that acts on the proliferation and differentiation of chondrocytes to promote bone growth.

HY-13302

CP-547632	Inhibitor	99.16%
CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2/KDR/Flk-1 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy.

HY-13302B

CP-547632 hydrochloride	Inhibitor	99.88%
CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2/KDR/Flk-1 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy.

HY-132817

Gunagratinib	Inhibitor	99.36%
Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135960

BO-264	Inhibitor	99.63%
BO-264 is a highly potent and orally active transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC₅₀ of 188 nM and a K_d of 1.5 nM. BO-264 specifically blocks the function of FGFR3-TACC3 fusion protein. BO-264 induces spindle assembly checkpoint (SAC)-dependent mitotic arrest, DNA damage and apoptosis. BO-264 has broad-spectrum antitumor activity.

HY-10209A

Masitinib mesylate	Inhibitor	99.83%
Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.

HY-N0060A

Ferulic acid sodium	Inhibitor	99.87%
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-145723

MAX-40279	Inhibitor
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

HY-107194

NSC12	Inhibitor	99.07%
NSC 12 is an extracellular trap of fibroblast growth factor 2 (FGF2) that binds FGF2 and interferes with its interaction with FGFR1. NSC12 inhibits the proliferation of different FGF-dependent tumour cells both in vitro and in vivo with no systemic toxic effects.

HY-16135

CEP-11981	Inhibitor	99.18%
CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects.

HY-101493

SUN11602		98.80%
SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.

HY-112452

SU11652	Inhibitor	99.06%
SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.

HY-145895

SNIPER(TACC3)-11	Inhibitor	99.58%
SNIPER(TACC3)-11 is a potent FGFR3-TACC3 degrader. SNIPER(TACC3)-11 reduces FGFR3-TACC3 protein levels and suppressed the growth of FGFR3-TACC3 positive cancer cells.

HY-156618

Irpagratinib	Inhibitor	99.63%
Irpagratinib (ABSK011) is an orally active inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, targeting to FGFR4 (IC50<10 nM). Irpagratinib inhibits the auto-phosphorylation of FGFR4 and blocks signal transduction from FGFR4 to downstream pathway activation. Irpagratinib exhibits high exposure in PK study in mouse, rat and dog, and also shows antineoplastic/anti-tumor activity in subcutaneous xenograft tumor models.

HY-N0183S4

Formononetin-d₃-1	Inhibitor	99.67%
Formononetin-d₃-1 is the deuterium-labeled Formononetin (HY-N0183).

HY-156632

Resigratinib	Inhibitor	99.53%
Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect.

Name
Email *

	Sorry, but the email address you supplied was invalid.